Clinical trials: copd or chronic obstructive
Pulmonary Disease, Chronic Obstructive, Asthma
Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients
The purpose of this study is to investigate the lung deposition and distribution pattern of Beclometasone and Formoterol using a gamma-scintigraphic technique after inhalation of a single dose of 99mTc-radiolabelled…
- Trial name
- NCT01176747
- Testing
- BDP/formoterol NEXT DPI
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Lymphoma, Non-Hodgkin's Lymphoma
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
The purpose of this study is to determine the long-term (> 6 months) safety of PCI 24781 PO in subjects with lymphoma.
- Conditions
- Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma
- Trial name
- NCT01149668
- Testing
- PCI-24781
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Pharmacyclics LLC.
Emphysema, Acute Respiratory Distress Syndrome
Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure
A new artificial lung device has been developed that potentially provides added support to mechanical ventilation for severely damaged lungs.
- Conditions
- Emphysema, Acute Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT00288964
- Testing
- Hattler Respiratory Assist Catheter
- Where
- United Kingdom
- Sponsor
- Alung Technologies
Pulmonary Disease, Chronic Obstructive
Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive Pulmonary Disease) Patients
This study will assess the effects of single oral doses of SB681323 and prednisolone on biomarkers in induced sputum and blood COPD patients
- Trial name
- NCT00380133
- Testing
- SB681323, Prednisolone
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants
TETRIS is a multi-center, prospective observational cohort study. It will include participants with COPD who are on an existing combined treatment of long-acting muscarinic antagonist (LAMA), long-acting beta 2 agonists (LABA)…
- Trial name
- TETRIS (NCT04657211)
- Testing
- Prospective observational cohort study
- Where
- Germany
- Volunteers
- 1,212 people
- Sponsor
- GlaxoSmithKline
Myelodysplastic Syndromes
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
Evaluate the safety and efficacy of oral azacitidne (CC-486) twice daily (BID) in subjects with myelodysplastic syndromes who failed to achieve an objective response post injectable hypomethylating agent (iHMA) treatment Reason…
- Trial name
- NCT02281084
- Testing
- Oral Azacitidine, Durvalumab
- Where
- 89 sites in United States, Australia and 8 more
- Volunteers
- 65 people
- Sponsor
- Celgene
Pulmonary Disease, Chronic Obstructive
Re-usable Respimat® Soft MistTM Inhaler Study
The study is to assess patient satisfaction with the inhaler attributes of the re-usable Respimat SMI (Spiriva, Striverdi or Spiolto) in patients with COPD, including patients who are Respimat SMI-experienced and Respimat…
- Trial name
- NCT04011735
- Testing
- Respimat
- Where
- 20 sites in Belgium, Denmark and 4 more
- Volunteers
- 262 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to characterize the dose-response profile of peak and trough FEV1 after single dose administrations of carmoterol in patients with COPD.
- Trial name
- NCT00782535
- Testing
- CHF 4226 pMDI
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD
A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD
The purpose of this study is to investigate the efficacy, safety and tolerability of AD 237 in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00242333
- Testing
- AD 237
- Where
- 33 sites in Bulgaria, Hungary and 2 more
- Volunteers
- 300 people
- Sponsor
- Sosei
COPD Exacerbation
Early Detection of COPD Exacerbations Using Home Monitoring Device
The goal of this observational study is to evaluate the safety and effectiveness of a home-monitoring device (RespirAI) in the early detection of COPD exacerbations in adults (age >21) with physician-diagnosed COPD who are at…
- Trial name
- NCT07554352
- Testing
- RespirAI
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- RespirAI US Inc
Pulmonary Disease, Chronic Obstructive
Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations
This was a retrospective cohort design using administrative claims data from Jan 1, 2003 through Sep 30, 2007, representing the years of available data, were used for this study.
- Trial name
- NCT01381406
- Testing
- TIO, TIO+FSC
- Volunteers
- 3,333 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to further figure out differences of glycopyrronium bromide compared to tiotropium in early bronchodilation measured by a comprehensive assessment of lung function that includes hyperinflation and…
- Trial name
- FAST (NCT01922271)
- Testing
- NVA237, Tiotropium, Salbutamol
- Where
- 14 sites in Germany
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)
To compare the persistence in using two different medications from the same drug class (LAMA/LABA FDC) which are delivered through different devices, a dry-powder inhalers (DPI) and Soft Mist Inhalers (SMI).
- Trial name
- NCT03979807
- Testing
- Olodaterol/Tiotropium Bromide, Umeclidinium/ Vilanterol
- Where
- United States
- Volunteers
- 11,296 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Functional Respiratory Imaging Study (FRI)
The purpose of this study is to evaluate the effect of inhaled extrafine CHF5993 pMDI on airway volumes, and resistance, by Functional Respiratory Imaging (FRI), in COPD patients
- Trial name
- FRI (NCT03268226)
- Testing
- Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
- Where
- 5 sites in Belgium, Hungary
- Volunteers
- 20 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of the study is to demonstrate the triple combination of beclometasone dipropionate + formoterol fumarate + glycopyrronium bromide is effective in term of quality of life in COPD patients (Chronic Obstructive…
- Trial name
- NCT02467452
- Testing
- BDP/FF/GB, FlF/VI + Tiotropium
- Where
- Hungary
- Volunteers
- 1,479 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects
GSK2269557 is potent and highly selective inhaled phosphoinositides 3-kinases -delta (PI3K-delta) inhibitor being developed as an anti-inflammatory agent for the treatment of inflammatory airway diseases.
- Trial name
- NCT01762878
- Testing
- GSK2269557
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Rhinosinusitis With Nasal Polyps, Asthma
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives To evaluate the efficacy of dupilumab in improving chronic…
- Trial name
- EVEREST (NCT04998604)
- Testing
- Dupilumab, Omalizumab
- Where
- 87 sites in United States, Belgium and 15 more
- Volunteers
- 360 people
- Sponsor
- Sanofi
COPD (Chronic Obstructive Pulmonary Disease)
Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients
This multicenter, retrospective-prospective, cohort study aims to evaluate the effectiveness and safety of Extra-fine Beclometasone Diproprionate/Formoterol Fumarate/Glycopyrronium Bromide (EF-BDP/FF/GB) therapy in adults with…
- Trial name
- RETRIBUTE (NCT07406048)
- Testing
- BDP/FF/GB (100ug/6ug/12.5ug)
- Where
- Brazil
- Volunteers
- 396 people
- Sponsor
- Chiesi Farmaceutica Ltda.
Chronic Obstructive Pulmonary Disease
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
This study was conducted to provide detailed information on the efficacy of indacaterol in terms of its effect on spirometry assessed forced expiratory volume in 1 second (FEV1) over a 24 hour time period.
- Trial name
- NCT00622635
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 14 sites in United States, Belgium and 1 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Emphysema
Post-Market Clinical Evaluation of the Zephyr Valve 5.5-LP EBV
This is a Post-Market Evaluation of the Zephyr Valve 5.5-LP EBV to assess Treated Lobar Volume Reduction (TLVR), changes in lung function and the safety profile of the Zephyr Valve treatment with the use of at least one Zephyr…
- Trial name
- NCT04161235
- Testing
- The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP
- Where
- 3 sites in Germany, Switzerland and 1 more
- Volunteers
- 2 people
- Sponsor
- Pulmonx Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.